Paul working for you.

Wednesday, April 15, 2020

#FireFauci


#FireFauci

Petition: #FireFauci

April 3, 2020
Donald J. Trump,
President of the United States
RE: Indictment & Firing of Anthony Fauci

Dear Mr. President,

I am signing this petition to sincerely request your Administration immediately indict and fire Dr. Anthony Fauci. I agree with Dr. Shiva Ayyadurai’s assessment, which he stated in a Letter to you on March 23, 2020, that:

“The current trajectory of Dr. Anthony Fauci’s public ‘health’ policy will result in the short- and long-term destruction of our citizen’s immune health as well as our nation’s economic health – perhaps a conscious and intended goal. Dr. Fauci’s policy, at best, is based on a 1950s outdated ‘one-size-fits-all,’ non-personalized approach to medicine and public health; and, at worst is derived from a ‘fake science’ understanding of the immune system – one, which Dr. Fauci, over five decades has perpetuated, and exploited to build his career.”

Dr. Fauci has significant and deep conflicts of interest with Big Pharma that has a singular aim: Force medical mandates e.g. vaccines upon all Americans. Big Pharma is failing, and is in economic peril. Forced and mandated vaccines are the only path for Big Pharma’s future.

During Dr. Fauci’s tenure, Americans have been led down a path of corporate solutions delivering policies that have led America to the lowest longevity rates, and highest infant mortality rates, in the western world.

In the current situation purposely driven by fearmongering and fake science, Dr. Fauci, his allies – Big Pharma, Gates Foundation, Clinton Global Initiative, Chan-Zuckerberg, WHO, CDC – and, the Chinese Communist Party (CPC), will profit enormously, both politically and economically, at the expense of the American working people.

It is time we focus on the Immune Health of the American people, which Big Pharma has zero interest in advancing. It is time we fire and indict Anthony Fauci to send a much-needed and long-awaited signal to his Big Pharma allies.

Thank you.

Petition

 

Link to Sign Petition

 







Show me the money!

How much moola can you make off of patents?

Patents by Inventor Anthony S. Fauci
Anthony S. Fauci has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).
  • Use of antagonists of the interaction between HIV GP120 and ?4?7 integrin
    Patent number: 9896509
    Abstract: Methods are provided for the treatment of a HIV infection. The methods can include administering to a subject with an HIV infection a therapeutically effective amount of an agent that interferes with the interaction of gp120 and ?4 integrin, such as a ?4?1 or ?4?7 integrin antagonist, thereby treating the HIV infection. In several examples, the ?4 integrin antagonist is a monoclonal antibody that specifically binds to a ?4, ?1 or ?7 integrin subunit or a cyclic hexapeptide with the amino acid sequence of CWLDVC. Methods are also provided to reduce HIV replication or infection. The methods include contacting a cell with an effective amount of an agent that interferes with the interaction of gp120 and ?4 integrin, such as a ?4?1 or ?4?7 integrin antagonist. Moreover, methods are provided for determining if an agent is useful to treat HIV.
    Type: Grant
    Filed: August 3, 2016
    Date of Patent: February 20, 2018
    Assignee: The United States of America, as Represented by the Secretary, Department of Health and Human Services
    Inventors: James Arthos, Diana Goode, Claudia Cicala, Anthony S. Fauci
  • USE OF ANTAGONISTS OF THE INTERACTION BETWEEN HIV GP120 AND A4B7 INTEGRIN
    Publication number: 20160333097
    Abstract: Methods are provided for the treatment of a HIV infection. The methods can include administering to a subject with an HIV infection a therapeutically effective amount of an agent that interferes with the interaction of gp120 and ?4 integrin, such as a ?4?1 or ?4?7 integrin antagonist, thereby treating the HIV infection. In several examples, the ?4 integrin antagonist is a monoclonal antibody that specifically binds to a ?4, ?1 or ?7 integrin subunit or a cyclic hexapeptide with the amino acid sequence of CWLDVC. Methods are also provided to reduce HIV replication or infection. The methods include contacting a cell with an effective amount of an agent that interferes with the interaction of gp120 and ?4 integrin, such as a ?4?1 or ?4?7 integrin antagonist. Moreover, methods are provided for determining if an agent is useful to treat HIV.
    Type: Application
    Filed: August 3, 2016
    Publication date: November 17, 2016
    Applicant: THE UNITED STATES OF AMERICA, as represented by the Secretary, Department of Health and Human Serv
    Inventors: James Arthos, Diana Goode, Claudia Cicala, Anthony S. Fauci
  • Use of antagonists of the interaction between HIV GP120 and ?4?7 integrin
    Patent number: 9441041
    Abstract: Methods are provided for the treatment of a HIV infection. The methods can include administering to a subject with an HIV infection a therapeutically effective amount of an agent that interferes with the interaction of gp120 and ?4 integrin, such as a ?4?1 or ?4?7 integrin antagonist, thereby treating the HIV infection. In several examples, the ?4 integrin antagonist is a monoclonal antibody that specifically binds to a ?4, ?1 or ?7 integrin subunit or a cyclic hexapeptide with the amino acid sequence of CWLDVC. Methods are also provided to reduce HIV replication or infection. The methods include contacting a cell with an effective amount of an agent that interferes with the interaction of gp120 and ?4 integrin, such as a ?4?1 or ?4?7 integrin antagonist. Moreover, methods are provided for determining if an agent is useful to treat HIV.
    Type: Grant
    Filed: September 21, 2015
    Date of Patent: September 13, 2016
    Assignee: The United States of America, as Represented by the Secretary, Department of Health and Human Services
    Inventors: James Arthos, Diana Goode, Claudia Cicala, Anthony S. Fauci
  • USE OF ANTAGONISTS OF THE INTERACTION BETWEEN HIV GP120 AND A4B7 INTEGRIN
    Publication number: 20160075786
    Abstract: Methods are provided for the treatment of a HIV infection. The methods can include administering to a subject with an HIV infection a therapeutically effective amount of an agent that interferes with the interaction of gp120 and ?4 integrin, such as a ?4?1 or ?4?7 integrin antagonist, thereby treating the HIV infection. In several examples, the ?4 integrin antagonist is a monoclonal antibody that specifically binds to a ?4, ?1 or ?7 integrin subunit or a cyclic hexapeptide with the amino acid sequence of CWLDVC. Methods are also provided to reduce HIV replication or infection. The methods include contacting a cell with an effective amount of an agent that interferes with the interaction of gp120 and ?4 integrin, such as a ?4?1 or ?4?7 integrin antagonist. Moreover, methods are provided for determining if an agent is useful to treat HIV.
    Type: Application
    Filed: September 21, 2015
    Publication date: March 17, 2016
    Applicant: The United States of America, as Represented by the Secretary, Department of Health and Human Serv
    Inventors: James Arthos, Diana Goode, Claudia Cicala, Anthony S. Fauci
  • IMMUNOCONJUGATES COMPRISING CD4 AND IMMUNOGLOBIN MOLECULES FOR THE TREATMENT OF HIV INFECTION
    Publication number: 20090285815
    Abstract: Nucleic acids encoding recombinant CD4-fusion proteins are disclosed herein that include a CD4 polypeptide ligated at its C-terminus with a portion of an immunoglobulin comprising a hinge region and a constant domain of a mammalian immunoglobulin heavy chain. The portion of the IgG is fused at its C-terminus with a polypeptide comprising a tailpiece from the C terminus of the heavy chain of an IgA antibody or a tailpiece from a C terminus of the heavy chain of an IgM antibody. Also disclosed herein are methods for using these CD4-fusion proteins.
    Type: Application
    Filed: March 21, 2008
    Publication date: November 19, 2009
    Inventors: James Arthos, Claudia Cicala, Anthony S. Fauci
  • Fusion protein including of CD4
    Patent number: 7368114
    Abstract: Novel recombinant polypeptides are disclosed herein that include a CD4 polypeptide ligated at its C-terminus with a portion of an immunoglobulin comprising a hinge region and a constant domain of a mammalian immunoglobulin heavy chain. The portion or the IgG is fused at its C-terminus with a polypeptide comprising a tailpiece from the C-terminus of the heavy chain of an IgA antibody ara tailpiece from a C-terminus of the heavy chain of an IgM antibody. Also disclosed herein are methods for using these CD4 fusion proteins.
    Type: Grant
    Filed: October 24, 2002
    Date of Patent: May 6, 2008
    Assignee: The United States of America as represented by the Department of Health and Human Services
    Inventors: James Arthos, Claudia Cicala, Anthony S. Fauci
  • HIV related peptides
    Patent number: 6911527
    Abstract: This invention is the discovery of novel specific epitopes and antibodies associated with long term survival of HIV-1 infections. These epitopes and antibodies have use in preparing vaccines for preventing HIV-1 infection or for controlling progression to AIDS.
    Type: Grant
    Filed: January 7, 2000
    Date of Patent: June 28, 2005
    Assignee: The United States of America as represented by the Secretary of the Department of Health and Human Services
    Inventors: Giuseppe Scala, Xueni Chen, Oren J. Cohen, Anthony S. Fauci
  • Efficient inhibition of hiv-1 viral entry through a novel fusion protein including of cd4
    Publication number: 20040265306
    Abstract: Novel recombinant polypeptides are disclosed herein that include a CD4 polypeptide ligated at its C-terminus with a portion of an immunoglobulin comprising a hinge region and a constant domain of a mammalian immunoglobulin heavy chain. The portion of the IgG is fused at its C-terminus with a polypeptide comprising a tailpiece from the C-terminus of the heavy chain of an IgA antibody or a tailpiece from a C-terminus of the heavy chain of an IgM antibody. Also disclosed herein are methods for using these CD4-fusion proteins.
    Type: Application
    Filed: July 27, 2004
    Publication date: December 30, 2004
    Inventors: James Arthos, Claudia Cicala, Anthony S. Fauci
  • Immunologic enhancement with intermittent interleukin-2 therapy
    Publication number: 20030180254
    Abstract: A method for activating a mammalian immune system entails a series of IL-2 administrations that are effected intermittently over an extended period. Each administration of IL-2 is sufficient to allow spontaneous DNA synthesis in peripheral blood or lymph node cells of the patient to increase and peak, and each subsequent administration follows the preceding administration in the series by a period of time that is sufficient to allow IL-2 receptor expression in peripheral or lymph node blood of the patient to increase, peak and then decrease to 50% of peak value. This intermittent IL-2 therapy can be combined with another therapy which targets a specific disease state, such as an anti-retroviral therapy comprising, for example, the administration of AZT, ddI or interferon alpha. In addition, IL-2 administration can be employed to facilitate in situ transduction of T cells in the context of gene therapy.
    Type: Application
    Filed: January 23, 2003
    Publication date: September 25, 2003
    Applicant: The Govt. of the USA as represented by the Secretary of the Dept. of Health & Human Services
    Inventors: H. Clifford Lane, Joseph A. Kovacs, Anthony S. Fauci
  • Immunologic enhancement with intermittent interleukin-2 therapy
    Patent number: 6548055
    Abstract: A method for activating a mammalian immune system entails a series of IL-2 administrations that are effected intermittently over an extended period. Each administration of IL-2 is sufficient to allow spontaneous DNA synthesis in peripheral blood or lymph node cells of the patient to increase and peak, and each subsequent administration follows the preceding administration in the series by a period of time that is sufficient to allow IL-2 receptor expression in peripheral or lymph node blood of the patient to increase, peak and then decrease to 50% of peak value. This intermittent IL-2 therapy can be combined with another therapy which targets a specific disease state, such as an anti-retroviral therapy comprising, for example, the administration of AZT, ddI or interferon alpha. In addition, IL-2 administration can be employed to facilitate in situ transduction of T cells in the context of gene therapy.
    Type: Grant
    Filed: August 9, 2000
    Date of Patent: April 15, 2003
    Assignee: The United States of America as represented by the Department of Health and Human Services
    Inventors: H. Clifford Lane, Joseph A. Kovacs, Anthony S. Fauci
  • Immunologic enhancement with intermittent interleukin-2 therapy
    Patent number: 6190656
    Abstract: A method for activating a mammalian immune system entails a series of IL-2 administrations that are effected intermittently over an extended period. Each administration of IL-2 is sufficient to allow spontaneous DNA synthesis in peripheral blood or lymph node cells of the patient to increase and peak, and each subsequent administration follows the preceding administration in the series by a period of time that is sufficient to allow IL-2 receptor expression in peripheral or lymph node blood of the patient to increase, peak and then decrease to 50% of peak value. This intermittent IL-2 therapy can be combined with another therapy which targets a specific disease state, such as an anti-retroviral therapy comprising, for example, the administration of AZT, ddI or interferon alpha. In addition, IL-2 administration can be employed to facilitate in situ transduction of T cells in the context of gene therapy.
    Type: Grant
    Filed: September 2, 1997
    Date of Patent: February 20, 2001
    Assignee: The United States of America as represented by the Department of Health and Human Services
    Inventors: H. Clifford Lane, Joseph A. Kovacs, Anthony S. Fauci
  • Immunologic enhancement with intermittent interleukin-2 therapy
    Patent number: 5696079
    Abstract: A method for activating a mammalian immune system entails a series of IL-2 administrations that are effected intermittently over an extended period. Each administration of IL-2 is sufficient to allow spontaneous DNA synthesis in peripheral blood or lymph node cells of the patient to increase and peak, and each subsequent administration follows the preceding administration in the series by a period of time that is sufficient to allow IL-2 receptor expression in peripheral or lymph node blood of the patient to increase, peak and then decrease to 50% of peak value. This intermittent IL-2 therapy can be combined with another therapy which targets a specific disease state, such as an anti-retroviral therapy comprising, for example, the administration of AZT, ddI or interferon alpha. In addition, IL-2 administration can be employed to facilitate in situ transduction of T cells in the context of gene therapy.
    Type: Grant
    Filed: May 26, 1995
    Date of Patent: December 9, 1997
    Assignee: The United States of America as represented by the Department of Health and Human Services
    Inventors: H. Clifford Lane, Joseph A. Kovacs, Anthony S. Fauci





Posted by at

1 comment:

  1. Bob MApril 16, 2020 at 8:48 AM

    During the 2019–20 coronavirus pandemic Ayyadurai used social media to spread various conspiracy theories and misinformation about the pandemic. In January 2020 he claimed that the coronavirus was patented by the Pirbright Institute, but the patent he referenced relates to avian coronavirus, which infects birds, not SARS-CoV-2, the virus responsible for the pandemic.[47]

    He alleged that the coronavirus was spread by the "deep state" and accused Anthony Fauci, director of the National Institute of Allergy and Infectious Diseases, of being a "Deep State Plant". Ayyadurai called for Fauci to be fired.[48]

    In March 2020 he published an open letter to president Donald Trump where he wrote that a national lockdown was unnecessary and advocated that large doses of vitamins could prevent and cure the disease

    ReplyDelete

Subscribe to: Post Comments (Atom)